Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice

Laboratory Investigation

Volumn 88, Issue 11, 2008, Pages 1192-1203

  Salguero Palacios, Rebeca ^a   Roderfeld, Martin ^a   Hemmann, Stefanie ^a   Rath, Timo ^a   Atanasova, Srebrena ^a   Tschuschner, Annette ^a   Gressner, Olav A ^b   Weiskirchen, Ralf ^b   Graf, Jürgen ^c   Roeb, Elke ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

CRP2; GFAP; HSC; Liver; MMP; TIMP

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CELL PROTEIN; CYTOKINE; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR D; PROTEIN CRP2; THIOACETAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STELLATE CELL;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; HEPATOCYTES; LIVER; LIVER CIRRHOSIS; LYMPHOKINES; MICE; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-SIS; THIOACETAMIDE;

EID: 54949116520     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.91     Document Type: Article

References (36)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
2. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003;33:105-136.
3. Weiler-Normann C, Herkel J, Lohse AW. Mouse models of liver fibrosis. Z Gastroenterol 2007;45:43-50.
4. Schnur J, Olah J, Szepesi A, et al. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 2004;16:127-133.
5. Saez-Lara MJ, Frecha C, Martin F, et al. Transplantation of human CD34(+) stem cells from umbilical cord blood to rats with thioacetamide-induced liver cirrhosis. Xenotransplantation 2006;13:529-535.
6. Honda H, Ikejima K, Hirose M, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36:12-21.
7. Kornek M, Raskopf E, Guetgemann I, et al. Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol 2006;45:370-376.
8. Dashti H, Jeppsson B, Hagerstrand I, et al. Thioacetamide- and carbon tetrachloride-induced liver cirrhosis. Eur Surg Res 1989;21:83-91.
9. Muller A, Machnik F, Zimmermann T, et al. Thioacetamide-induced cirrhosis-like liver lesions in rats - usefulness and reliability of this animal model. Exp Pathol 1988;34:229-236.
10. Nozu F, Takeyama N, Tanaka T. Changes of hepatic fatty acid metabolism produced by chronic thioacetamide administration in rats. Hepatology 1992;15:1099-1106.
11. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007;117:539-548.
12. Uyama N, Zhao L, Van RE, et al. Hepatic stellate cells express synemin, a protein bridging intermediate filaments to focal adhesions. Gut 2006;55:1276-1289.
13. Knittel T, Kobold D, Piscaglia F, et al. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochem Cell Biol 1999;112:387-401.
14. Morini S, Carotti S, Carpino G, et al. GFAP expression in the liver as an early marker of stellate cells activation. Ital J Anat Embryol 2005;110:193-207.
15. Weiskirchen R, Moser M, Weiskirchen S, et al. LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. Biochem J 2001;359:485-496.
16. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417.
17. Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995;24:759-786.
18. Neyzen S, Van de Leur E, Borkham-Kamphorst E, et al. Cryopreservation of hepatic stellate cells. J Hepatol 2006;44:910-917.
19. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-75.
20. Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 2006;20:444-454.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Hillebrandt S, Goos C, Matern S, et al. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002;123:2041-2051.
23. Li Z, Dranoff JA, Chan EP, et al. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007;46:1246-1256.
24. Han YP, Yan C, Zhou L, et al. An MMP-9 activation cascade by hepatic stellate cells in trans-differentiation in 3D extracellular matrix. J Biol Chem 2007;282:12928-12939.
25. Takahara T, Zhang LP, Yata Y, et al. Modulation of matrix metalloproteinase-9 in hepatic stellate cells by three-dimensional type I collagen: its activation and signaling pathway. Hepatol Res 2003;26:318-326.
26. Buniatian G, Hamprecht B, Gebhardt R. Glial fibrillary acidic protein as a marker of perisinusoidal stellate cells that can distinguish between the normal and myofibroblast-like phenotypes. Biol Cell 1996;87:65-73.
27. Buniatian GH. Stages of activation of hepatic stellate cells: effects of ellagic acid, an inhibiter of liver fibrosis, on their differentiation in culture. Cell Prolif 2003;36:307-319.
28. Neubauer K, Knittel T, Aurisch S, et al. Glial fibrillary acidic protein - a cell type specific marker for Ito cells in vivo and in vitro. J Hepatol 1996;24:719-730.
29. Herrmann J, Borkham-Kamphorst E, Haas U, et al. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-beta in smooth muscle and hepatic stellate cells. Biochem Biophys Res Commun 2006;345:1526-1535.
30. Magness ST, Bataller R, Yang L, et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004;40:1151-1159.
31. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397-416.
32. Patrick AL, Rullo J, Beaudin S, et al. Hepatic leukocyte recruitment in response to time-limited expression of TNF-alpha and IL-1beta. Am J Physiol Gastrointest Liver Physiol 2007;293:663-672.
33. Knittel T, Mehde M, Grundmann A, et al. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol 2000;113:443-453.
34. Roderfeld M, Geier A, Dietrich CG, et al. Cytokine blockade inhibits hepatic tissue inhibitor of metalloproteinase-1 expression and up-regulates matrix metalloproteinase-9 in toxic liver injury. Liver Int 2006;26:579-586.
35. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002;36:973-977.
36. Dai K, Qi JY, Tian DY. Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. World J Gastroenterol 2005;11:4822-4826.